This finding is in line with the results of the randomized controlled NeoSphere study, in which 51 patients with HR+/HER2+ breast cancer were treated with trastuzumab and pertuzumab without chemotherapy or ET, resulting in a ypT0 rate in the breast of 5.9% [12]. This evidence concerns the gene HR and breast carcinoma.